Editor's letter

Issue 148 • November 2024

Don’t miss out – sign up to our free industry-leading magazine and newsletters

Cover image: 
Credit: XY

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

The growing global demand for cell and gene therapies (CGTs) is resulting in a manufacturing paradigm shift, reflecting the need to overcome a range of evolving new challenges and adapt to maintain rigorous safety and efficacy standards.

This month’s cover story looks at how the acceleration in CGT approvals in recent years not only highlights the potential of these therapies, but also underscores the growing demand for specialised and expanded manufacturing capabilities.

Also in this issue, a feature examines what lessons researchers can take from the Covid-19 pandemic to address the growing mpox public health emergency. Ten years after Bristol Myers Squibb’s (BMS) Opdivo, Merck & Co’s Keytruda were approved, they continue to be major revenue drivers for the respective companies. An opinion piece assesses the market entry strategies, pricing dynamics over time of both drugs. All this, along with the latest news and deals in the pharmaceutical landscape.

Ross Law, deputy editor

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue